Recruiting

Testing a new medication for hot flashes and night sweats in midlife women

Plain-English translation of NCT07042516 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated October 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing (TP0052), a new medication designed to reduce the frequency and severity of hot flashes and night sweats—also called vasomotor symptoms—that many women experience during midlife. The medication works in a different way than other available treatments, by targeting receptors in the body that may control temperature regulation. Researchers want to learn whether this treatment is safe and actually works better than placebo.

Many women suffer from severe hot flashes and night sweats that disrupt their daily life and sleep, but current treatment options are limited or don't work well for everyone. This trial is exploring a new approach that may offer an alternative for women seeking relief.

Do you qualify?

You likely qualify if…

you are a woman aged 40–62 years old
you are experiencing at least 40 moderate to severe hot flashes or night sweats per week, including at least 6 per day on 4 or more days each week
you have not taken medications for hot flashes or night sweats recently (such as SSRIs, gabapentin, or other similar drugs)
you are menopausal or in late perimenopause (confirmed by your medical history or blood tests)
you are in general good health, as determined by your doctor

You likely don't qualify if…

you have used hormone therapy or hormonal birth control in the past 8 weeks
you have taken non-hormonal medications for hot flashes (like SSRIs, gabapentin, or clonidine) in the past 4 weeks
you are using cannabis or marijuana products in any form except topical applications
you are using herbal or dietary supplements designed to reduce hot flashes

What participation looks like

You would first complete a 2-week screening period where you log your hot flashes daily to confirm you qualify. If you do, you would be randomly assigned to receive either the new medication or a placebo (dummy pill), taking four tablets by mouth each day for 8 weeks. After that, everyone gets 4 weeks of the actual medication. You'll have follow-up visits to report how you're doing and check for any side effects, with a final safety check around week 12. Some participants may also choose optional non-invasive tests to measure blood vessel and heart health at the beginning and end of the study.

AI-generated summary from trial data · Oct 12, 2026 · Not medical advice

Testing a new medication for hot flashes and night sweats in midlife women

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)